Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

https://www.soho2019.com/

 

Acute Myeloid Leukemia
15:38

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

2019 AML State of the Art Update: How to Treat Newly Diagnosed and Secondary AML, New AML Workup, Newer FLT3 Mutations, BCL-2 Inhibition, With Case Examples

FEATURING Selina Luger
  • 448 views
  • October 17, 2019
  • 4
16:27

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

CAR T-Cells in AML: An Effective Therapy Requires Optimization of the CAR Design, Manufacturing Platform and Combinational Therapy

FEATURING Elizabeth Budde
  • 32 views
  • October 18, 2019
13:57

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Novel Strategies in High Risk AML: Clinical and Molecular Features

FEATURING John Welch
  • 19 views
  • October 17, 2019
16:06

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Chemotherapy-Free Approach in Relapsed/Refractory AML: Antibody-Drug Conjugates, Dual Affinity Re-Targeting (DART) and Bi-Specific T-Cell Engagers (BiTEs)

FEATURING John DiPersio
  • 313 views
  • October 18, 2019
  • 1
15:39

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

All Older AML Patients and Younger Patients with Adverse Biology Should Receive HMA/Venetoclax Instead of 3+7/Standard Induction

FEATURING Daniel Pollyea
  • 1,014 views
  • October 17, 2019
  • 8
17:20

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

HMA/Ventoclax vs. 3+7/Standard Induction - Should All Older and Younger AML Patients with Adverse Biology Routinely Receive It?

FEATURING Jeffrey Lancet
  • 41 views
  • October 18, 2019
15:19

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Use of MRD in AML: Determining Method, Acceptable Endpoint and Prognostic Significance in Younger/Intensively Treatment Patients and Older Less/Intensively Treated Patients

FEATURING Pau Montesinos
  • 19 views
  • October 18, 2019
14:52

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

How to Choose a FLT3 inhibitor in AML in 2019: Discussion on Midostaurin, Quizartinib, Crenolanib and Gilteritinib

FEATURING Catherine Smith
  • 41 views
  • October 18, 2019
15:52

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Use of Gemtuzumab in CD33 + AML: Benefit May Be Greatest in Favorable-Risk AML

FEATURING Roland B. Walter
  • 18 views
  • October 18, 2019
08:26

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Synergistic Activity of the MCL-1 Inhibitor S63845 with Midostaurin in Preclinical Human Models of FLT3- ITD Mutated AML - Inhibiton of Mcl-1 Improves Anti-Leukemia Efficacy

FEATURING Anna Skwarska
  • 21 views
  • October 18, 2019
09:44

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

The Promising Data on Efficacy of Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed AML

FEATURING Courtney D. DiNardo
  • 26 views
  • October 18, 2019
08:59

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Genome-Wide CRISPR-Cas9 Screen Identifies XPO7 as a Novel Therapeutic Target for TP53-Mutated AML

FEATURING Yuichiro Semba
  • 10 views
  • October 18, 2019